A distinct clinical entity consisting of a highly impaired interferon (IFN) type I response has been observed in critically ill patients with COVID-19, characterized by the absence of IFN-β and by low IFN-α production associated with a persistent blood viral load and inflammatory response (12). Here, IFNA1 is linked to COVID-19.